Parkinson's disease (PD) is characterized by motor symptoms including resting tremor, rigidity, and bradykinesia. However, cognitive and behavioral problems in PD are common 1 and can have a significant effect on quality of life. 2, 3 The prevalence of dementia in patients with PD has conservatively been estimated to range between 24 and 31%. 4 The cognitive profile observed in PD patients with dementia (PDD) is substantially different from that of the primarily cortical dementia of Alzheimer's disease (AD). Patients with PDD typically exhibit difficulties with executive functions, the retrieval aspects of memory, and visuospatial skills. 4 They do not exhibit clear aphasia, apraxia, or agnosia, which are common features of AD. The onset of dementia in PD is insidious, typically occurring years after the onset of motor symptoms. However, cognitive difficulties have been observed even in early PD. 5 Although debated, the pattern of early cognitive dysfunction in PD is believed to be generally similar to that of PDD.
in PD is believed to be generally similar to that of PDD. 6, 7 The pathophysiology of cognitive symptoms in PD is believed to be different from that of the motor symptoms. [8] [9] [10] Several theories exist regarding the origins of this particular clinical manifestation. It is possible that cognitive dysfunction in PD is related to the depletion of striatal dopamine and its effect on non-motor cortico-striato-pallidalthalamocortical (CSPTC) circuits. 6 Nevertheless, other dopaminergic systems may mediate these cognitive changes, including mesocortical dopamine projections to the prefrontal cortex. 11, 12 Other pathological processes, such as regional cortical Lewy body formation, are also likely to contribute to PD cognitive decline, 13 as well as abnormalities of other neurotransmitter systems.
14 Metabolic Imaging 18 F-fluorodeoxyglucose (FDG) PET imaging has revealed widespread cortical hypometabolism in advanced PD patients relative to healthy controls. 15 Among patients with PD, those with dementia exhibit relatively greater metabolic reductions in both frontal and parietal regions. 16 Although not widely investigated, several imaging studies support the idea that multiple cortical regions are associated with changes in cognition. For example, performance on a complex spatial conceptual task (Raven's Colored Progressive Matrices) was found to be associated with reduced metabolic activity in the dorsolateral prefrontal cortex (DLPFC) and in the right retrosplenial region and posterior cingulate region. 17 Furthermore, changes in mesial frontal activity observed in normal controls performing a gambling task was not present in non-demented PD patients. 18 To identify metabolic brain networks associated with PD, we have applied a voxel-based spatial covariance approach to the analysis of PET data.
motor and cognitive aspects of PD (see Figure 1) . 7, 19 These networks have been demonstrated to be robust descriptors of disease processes. The PDCP does have some regional overlap with the PDRP. However, these network biomarkers are dissociable in multiple ways. 7, 10, 23, 24 In a longitudinal study 7 we documented that PDRP expression is elevated in early disease, whereas a significant degree of PDCP network expression cannot be discerned until approximately six years after symptom onset.
In other words, network expression parallels symptom onset, with the motor manifestations preceding cognitive dysfunction. In addition, PDRP expression is sensitive to pharmacological and surgical therapies directed at the motor manifestations of the disease. 22, 25 On the other hand, PDCP expression remains stable with these interventions, consistent with the lack of a treatment effect on cognitive functioning based on repeated psychometric testing. 10, 23 Subsequent studies have suggested that the PDCP is sensitive to early cognitive decline, as characterized by mild cognitive impairment (MCI). 26, 27 PDCP activity was found to increase in a stepwise fashion, with worsening cognitive categorization (see Figure 2 ). Healthy control subjects had lower PDCP expression than PD patients without MCI, who in turn had lower values than those with cognitive impairment.
Moreover, patients with single-domain MCI maintained an intermediate position between those with involvement of multiple cognitive domains and those without cognitive impairment. PDD patients exhibit further PDCP elevations than MCI subjects.
The anatomical regions that contribute most to the PDCP network are the medial aspects of the lateral frontal and parietal association areas, and are therefore somewhat reminiscent of the 'default mode network.' 28 Therefore, it is possible that abnormal elevations in PDCP activity denote reduced capacity to allocate neural resources, as well as a diminution in cognitive reserve. Given the lack of a significant effect of levodopa on PDCP expression, 10 this network is unlikely to be a simple reflection of mesocortical dopaminergic dysfunction. Moreover, PDCP regions do not generally display α-synuclein aggregation until later in the clinical course of disease. 29 It is therefore possible that in early stages of disease, this cognition-related pattern reflects functional changes in non-dopaminergic systems. Indeed, cholinergic deficits have been documented in multiple PDCP areas. 10, 14, 30 To date, there has been no direct comparison of PDCP expression and cholinergic functioning.
Dopaminergic Imaging
The development of several ligands for use with PET has helped elucidate the role of different mechanisms associated with cognitive Overall, based on FDODA uptake, caudate dopamine is believed to be more closely associated with cognition than dopamine in the putamen, 31, 34 although it has been suggested that both regions are linked to different aspects of cognition, 35 hypothesizing that the putamen is related to the executive aspect of motor initiation. Others have found that cortical FDOPA uptake in DLPFC and medial PFC is associated with executive functioning 34, 36 and conceptualization abilities. 17 Other radiotracers have been extensively utilized with PET and singlephoton-emission computed tomography (SPECT) to measure striatal dopamine transporter (DAT) binding in PD. 37 38, 39 We found a significant correlation between dopamine input to the caudate and cognitive functioning in early PD.
This study also revealed a relationship between caudate DAT binding and PFC activation during sequence learning.
In summary, imaging research targeting the dopaminegic system supports the existence of a substantial contribution from the mesocortical and nigrostriatal pathways to cognitive functioning in PD.
Nonetheless, these changes do not fully explain the impairment in cognitive functioning seen in these patients. Indeed, the behavioral response to dopaminergic treatment is complex and may involve a variety of phenotypic and genotypic factors. deposits are evident on histopathological studies. 42 Although less frequent than in diffuse Lewy body disease (DLB), cortical Aβ aggregates can be found in approximately one-fifth of PDD patients, 43 and elevated PIB binding on PET imaging has been noted in a similar proportion of these patients. [44] [45] [46] Interestingly, PDD patients with and without PIB activity do not appear to differ behaviorally, 44, 46 suggesting that focally increased amyloid deposition is not the cause of impaired cognitive functioning in these patients. PIB has been shown to bind to α-synuclein fibrils, although with a much lower affinity than to Aβ. 47 Nevertheless, PIB does not bind to DLB homogenates that are Aβ-plaque-free. 47 Thus, the role of α-synuclein aggregation in PD-related cognitive impairment remains an open issue. Moreover, the relationship between PIB burden and cognitive functioning has not been studied with comprehensive neuropsychological testing, although a clear relationship has been found with brief screening instruments. 
